ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Find A Clinical Trial

Disease Type: Lymphoma

Trial ID 18263
Sponsor ID Beigene

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Principal Investigator
Mitul Gandhi, MD
5 Locations
Trial ID 18013
Sponsor ID Seattle Genetics, Inc.

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects .  Ph2 A+AVD +G-CSF or AOAD in CHL

Principal Investigator
Mitul Gandhi, MD
5 Locations
Trial ID 19205
Sponsor ID TGI Therapeutics

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Principal Investigator
Mitul Gandhi, MD
5 Locations
Trial ID ADCT-301-201
Sponsor ID ADC Therapeutics

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Principal Investigator
Dipti Patel-Donnelly, MD
1 Location
Trial ID C2321001
Sponsor ID C2321001

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Trial ID ADCT-402-201
Sponsor ID ADCT-402-201

Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID LAM-002A-NHL-CLN01
Sponsor ID

A PHASE 1 DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF LAM-002A (APILIMOD DIMESYLATE CAPSULES) ADMINISTERED ORALLY IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA

Principal Investigator
Dipti Patel-Donnelly, MD
1 Location
Trial ID CTMX-M-2029-001
Sponsor ID CTMX-M-2029-001

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID 17-050
Sponsor ID

A Phase III, Multicenter, randomized, double-blind, placebo-controlled trial comparing the efficiacy and safety of polatuzumab vedotin in combination with rituximab and chip (R-CHIP) versus rituximab and chop (R-CHOP) in previously untreated patients with diffuse large b-cell lymphoma

Principal Investigator
Dipti Patel-Donnelly, MD
2 Locations
Trial ID STRO-001-BCM1
Sponsor ID STRO-001-BCM1

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location